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ABSTRACT
OBJECTIVE: To assess findings of mammography of and interventions 
resulting from breast cancer screening in women aged 40-49 years with no 
increased risk (typical risk) of breast cancer.
METHODS: This cross-sectional study evaluated women aged 40-49 years 
who underwent mammography screening in a mastology reference center in 
Recife, PE, Northeastern Brazil, between January 2010 and October 2011. 
Women with breast-related complaints, positive findings in the physical 
examination, or high risk of breast cancer were excluded.
RESULTS: The 1,000 mammograms performed were classified into the 
following Breast Imaging-Reporting and Data System (BI-RADS) categories 
BI-RADS 0, 232; BI-RADS 1, 294; BI-RADS 2, 294; BI-RADS 3, 16; 
BI-RADS 4A, 2; BI-RADS 5, 1. There was one case of grade II invasive 
ductal carcinoma and various interventions, including 469 ultrasound scans, 
53 referrals to mastologists, 11 cytological examinations, and 8 biopsies.
CONCLUSIONS: Mammography screening in women aged 40-49 years 
with typical risk of breast cancer led to the performance of other interventions. 
However, it also resulted in increased costs without demonstrable efficacy 
in decreasing mortality.
DESCRIPTORS: Women. Mammography. Mass Screening. Breast 
Neoplasms, diagnosis. Cross-Sectional Studies.
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The annual incidence of breast cancer varies widely 
worldwide, from 19.3 per 100,000 women in East 
Africa to 89.9 per 100,000 in Western Europe.4 This 
is related to the urbanization process. Accordingly, 
although the rates are higher in developed countries, 
in recent years, breast cancer incidence has increased 
in developing countries.4
In Brazil, breast cancer is the second most frequent 
type of cancer in the female population, preceded 
only by nonmelanoma skin cancer.a It is estimated that 
57,120 new cases will be diagnosed in 2014, with a 
risk of 56 cases per 100,000 women. Of these, 64.3% is 
predicted to occur in the northeast of Brazil.a Breast 
cancer is the fifth most common cause of death due to 
cancer in the general population and the most frequent 
cause of death due to cancer in women.b
Because the early detection of breast cancer (before 
there is a palpable nodule) increases the chances of 
survival,1 routine mammography screening and phys-
ical examination are recommended.15
Mammography is the best method for the early diagnosis 
of breast cancer, demonstrating a 15.0%-25.0% reduction 
RESUMO
OBJETIVO: Avaliar os achados mamográficos e as intervenções decorrentes 
do rastreamento em mulheres de 40 a 49 anos de idade com risco habitual para 
o câncer de mama.
MÉTODOS: Estudo transversal com mulheres de 40 a 49 anos, submetidas ao 
rastreamento mamográfico em centro de referência em mastologia, em Recife, 
PE, de janeiro de 2010 a outubro de 2011. Foram excluídas mulheres com queixas 
mamárias, alterações no exame físico e com alto risco para câncer de mama.
RESULTADOS: Das 1.000 mamografias realizadas, 232 foram BI-RADS 
0, 454 BI-RADS 1, 294 BI-RADS 2, 16 BI-RADS 3, duas BI-RADS 4A, 
uma BI-RADS 4C e uma BI-RADS 5. Observou-se um único caso de 
carcinoma ductal invasivo grau II e várias intervenções: 469 ultrassonografias, 
53 encaminhamentos para a mastologia, 11 citologias e oito biópsias.
CONCLUSÕES: O rastreamento mamográfico em mulheres de 40 a 49 anos 
com risco habitual para o câncer de mama leva a outras intervenções e, assim, 
ao aumento dos custos com eficácia não mostrada para redução da mortalidade.
DESCRITORES: Mulheres. Mamografia. Programas de Rastreamento. 
Neoplasias da Mama, diagnóstico. Estudos Transversais.
INTRODUCTION
in mortality among women undergoing breast cancer 
screening.6 Monthly breast self-examination could be 
an alternative to mammography screening owing to its 
simplicity and low cost.8 However, there is no evidence 
that it leads to decreased mortality. Furthermore, this 
practice is being abandoned because it causes more 
harm than good, such as unnecessary anxiety among 
women.10 Magnetic resonance imaging is recommended 
for screening only in women at high risk of breast cancer.9
Until date, there is no consensus about the perfor-
mance of mammography screening among women aged 
40-49 years.7 In this age group, breast cancer incidence 
is lower than that of patients aged 50-69 years,c but the 
occurrence of dense breasts and fast-growing tumors is 
higher.12 Breast cancer in young women remains poorly 
understood. It is believed that breast cancer is biologi-
cally more aggressive in young women, with more 
frequent adverse histopathological characteristics and 
worse prognoses than in older women.12
Studies of women aged 40-49 years not at high risk 
are necessary and should consider the peculiarities of 
each population to determine the ideal age for starting a 
mammography-based breast cancer screening program.
a Ministério da Saúde. Instituto Nacional de Câncer. Estimativa 2014: incidência do câncer no Brasil. Rio de Janeiro; 2013.
b Ministério da Saúde. Instituto Nacional de Câncer. Programa Nacional de Controle do Câncer de Mama. Programa Viva Mulher. Rio de Janeiro; 2011.
c Ministério da Saúde. Instituto Nacional de Câncer. SISMAMA - Informação para o avanço das ações de controle do câncer de mama no 
Brasil. Rio de Janeiro; 2010.
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The objective of this study was to assess the mammog-
raphy findings and interventions resulting from breast 
cancer screening in women aged 40-49 years with no 
increased risk (typical risk) of breast cancer.
METHODS
This cross-sectional study was conducted between 
January 2010 and October 2011 in Recife, PE, 
Northeastern Brazil, in the Department of Radiology 
at the Instituto de Medicina Integral Prof. Fernando 
Figueira (IMIP), a specialty center in mastology.
The sample size was calculated using the public 
domain software OpenEpi (Atlanta, GA), version 7. 
An incidence of 4.6% for positive mammography was 
obtained from the first mammography screening in this 
age group.14 Considering a 95% confidence level and 
power of 80.0%, a sample of 885 women was deemed 
required. To offset any potential losses, this number 
was increased to 1,000 women.
Women aged 40-49 years who underwent mammog-
raphy screening between January 2010 and October 
2011 were included in the study. Women with 
breast-related complaints (pain, nodule, nipple 
discharge, and increased breast volume) or posi-
tive findings in the physical examination (shrinkage, 
bulging, nodules, hardening, and nipple discharge) at 
the time of the physical examination were excluded, 
along with those at high risk of breast cancer and those 
with absent mammography reports.
Women with the following characteristics were consid-
ered to be at high risk of breast cancer: first-degree 
relative with breast cancer before age 50 years, male 
relative with breast cancer, first-degree relative with 
bilateral breast cancer or ovarian cancer at any age, 
histopathological diagnosis of a proliferative breast 
lesion with atypia or lobular neoplasia in situ, and 
personal history of breast or ovarian cancer.d Patients 
not presenting a high risk of the disease were consid-
ered to have typical risk.
The variables studied were as follows: exposure-related 
variables [age (years), ethnicity, education (years), 
age at menarche (years), use of hormone therapy, use 
of oral contraceptives, breastfeeding in any previous 
pregnancy, and age at first pregnancy (years)]; vari-
ables associated with sample characterization (origin 
and state of menopause); outcome-associated vari-
ables [Breast Imaging-Reporting and Data System 
(BI-RADS)];2 and descriptive variables [mammo-
graphic characteristics (breast density, nodules, calci-
fications, asymmetry, and structural distortions), 
interventions performed (ultrasound scans, referral to 
mastologists, cytological examination, and biopsy), 
and the result of histopathological examination of the 
biopsy, in the order of lesions with worsening prognosis 
(nonproliferative lesions, proliferative lesions without 
atypia, proliferative lesions with atypia, in situ carci-
noma, and invasive carcinoma)].
Cytological examination by fine-needle aspiration was 
indicated for patients with BI-RADS 4 and 5. For the 
other BI-RADS, cytological examination was indi-
cated according to the results of other complementary 
examinations.e Biopsy was performed for the same indi-
cations, according to the lesion characteristics, in cases 
that were inconclusive, equivocal, or different from 
the clinical and radiological diagnoses.e The samples 
were obtained through core biopsy or surgical biopsy.e
For patient selection, a list of all the women who had 
undergone mammography screening within the study 
period was obtained. Subsequently, patient records 
were obtained immediately afterward; the records were 
stamped to avoid the risk of selecting the same patients. 
The records of the patients aged 40-49 years were veri-
fied according to the inclusion and exclusion criteria. 
The mammography reports were obtained through the 
institution’s computer system.
During the study period, 3,574 mammograms were 
performed among the population of interest. Of these, 
2,076 were evaluated; the other 1,498 were excluded 
because they belonged to the same patient or because 
the patient records were not found. After verification, 
515 women were excluded from the total number 
of patients evaluated because they presented with 
complaints and/or physical changes and/or were at high 
risk, and 561 were excluded because the obtaining of 
mammography reports was not possible, leaving 1,000 
women for analysis (Figure).
The data were analyzed using the EpiInfo software 
(Atlanta, GA), version 7. For the descriptive analysis, 
the mean and its standard deviation (SD) were calcu-
lated for numeric variables, and frequency distribution 
was calculated for categorical variables.
To define the association between biological, sociodemo-
graphic, reproductive, and gynecological variables and 
BI-RADS categories 3, 4, and 5, we used the Chi-square 
test of association, or Fisher’s exact test where appro-
priate, with a significance level of 5%. To determine the 
strength of the association, the prevalence ratio (PR) 
was calculated along with its 95% confidence interval.
This study was approved by the Human Research 
Ethics Committee of the IMIP, under Presentation 
d Ministério da Saúde. Instituto Nacional de Câncer. Parâmetros técnicos para o rastreamento do câncer de mama. Rio de Janeiro; 2009.
e Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Básica. Controle dos cânceres do colo do útero e da mama. 
2. ed. Brasília (DF); 2013.
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Certificate for Ethical Consideration (CAAE − 
03191212.0.0000.5201 from 6/26/2012). Approval was 
obtained without requiring informed consent because 
of the retrospective nature of the study and because 
the collection of informed consent forms from all the 
women subjected to mammographic examination was 
not feasible.
RESULTS
The mean age was 45.2 (SD = 3.5) years. With regard 
to patients’ location, 827 (82.7%) patients were from 
the Recife Metropolitan Area, 171 (17.1%) were from 
other cities in Pernambuco, and two (0.2%) came from 
other states. Most of the women were of mixed race 
(n = 368; 62.4%) and only one (0.2%) was of indig-
enous origin. With regard to education, most women 
had completed 4-11 years of schooling (377; 64.3%) 
and 13 (2.2%) were illiterate (Table 1).
The mean age at menarche was 12.9 years (SD = 1.6), 
with a range of 9-19 years. Oral contraceptives 
were used by 58 (6.4%) women. Most patients were 
premenopausal (n = 681; 74.4%) and hormone-
replacement therapy was used by only 19 women 
(2.1%) (Table 1).
The mean age at first pregnancy was 22.3 years 
(SD = 5.1), with a range of 12-43 years; 57 patients gave 
birth at age ≥ 30 years and 95 women were nulliparous. 
In addition, 74.4% reported that they breast-fed their 
infants from at least one previous pregnancy (Table 1).
With regard to the mammography screening, 724 women 
(72.4%) had dense or moderately dense breasts, and 
276 (27.6%) had breasts totally or partially replaced by 
fat. Nodules were observed in 71 women; 65 (91.5%) 
were circumscribed and six (8.5%) were not circum-
scribed. Calcifications were observed in 295 mammo-
grams; 291 (98.6%) were benign, three (1.0%) were 
suspicious, and one (0.3%) was malignant. In addition, 
63 mammograms (6.3%) were asymmetrical, and three 
(0.3%) showed structural distortions (Table 2).
With regard to BI-RADS categories, 232 (23.2%) were 
inconclusive (BI-RADS 0), 454 (45.4%) were nega-
tive for malignancy (BI-RADS 1), 294 (29.4%) were 
benign (BI-RADS 2), 16 (1.6%) were probably benign 
(BI-RADS 3), two (0.2%) had low suspicion of malig-
nancy (BI-RADS 4A), one (0.1%) had moderate suspi-
cion of malignancy (BI-RADS 4C), and one (0.1%) had 
high suspicion of malignancy (BI-RADS 5) (Table 2).
Of the 1,000 mammograms evaluated, 160 (16.1%) 
were requested by mastologists, 833 (83.9%) by gyne-
cologists, and the remaining seven by other special-
ists. Among 833 examinations requested by gynceolo-
gists, 53 (5.3%) cases were referred to mastologists. 
Ultrasound examination was requested for 469 women, 
with 182 of these being requested concurrently with 
mammography (Table 3). In the cases that underwent 
concurrent mammography and ultrasound examina-
tions, mastologists requested for both mammography 
and ultrasound scans in 46.0% of the cases, whereas 
obstetricians requested these examinations in 13.0% of 
the cases (p = 0.0001).
Eleven cases underwent cytological examination. Two 
cytological examinations were considered unsatisfactory 
in patients with breast nodules and BI-RADS 0. Five 
examinations revealed nonproliferative benign lesions 
Figure. Flowchart of participant selection.
Ineligible (n = 515)
Women with breast complaints 
when the mammography 
was requested and/or 
changes in the physical 
examination and/or high risk
Files without reports
(n = 561)
Eligible (n = 1,000)
Women aged 40-49 years, 
asymptomatic and without 
high risk factors for breast cancer
IMIP Archive
Collect files
(n = 2,076)
Files not found 
or duplicates
(n = 1,498)
IMIP Radiology Department
Listing of mammographies 
of women aged 40-49 years
(n = 3,574)
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in patients with breast nodules, with three of these with 
BI-RADS 0 and two with BI-RADS 1. Four examinations 
revealed fibroadenoma in patients with breast nodules 
whose mammographies were BI-RADS 0 (Table 3).
Biopsies were performed in eight cases. Two cases showed 
nonproliferative lesions in patients with breast nodules 
(one with noncircumscribed nodules and BI-RADS 2 
and the other with BI-RADS 1 who had already under-
gone cytological examinations). Five showed prolifera-
tive lesions without atypia in patients with breast nodules, 
three of which had BI-RADS 0 (one with noncircum-
scribed nodule and two with BI-RADS 2). The remaining 
case showed invasive ductal carcinoma, grade II, with the 
mammogram showing microcalcifications and BI-RADS 
5 (Table 3). In this case, the immunohistochemical exami-
nation was positive for estrogen and progesterone recep-
tors and negative for HER-2 (1+). The patient was in 
clinical stage IIIb and had undergone neoadjuvant chemo-
therapy followed by mastectomy. After surgical treatment, 
the patient underwent radiotherapy followed by hormone 
therapy with tamoxifen. At present, the patient is being 
monitored for breast cancer, without clinical signs of recur-
rence or distant disease 10 months after surgery.
Table 1. Profile of women aged 40-49 years subjected to 
mammographic screening. Recife, PE, Northeastern Brazil, 
2010-2011. (N = 1,000)
Variable n %
Age (years)
40 to 44 465 46.5
45 to 49 535 53.5
Ethnicity
Caucasian 137 23.2
Mixed 368 62.4
Black 75 12.7
East Asian 9 1.5
Indigenous 1 0.2
Origin
Recife Metropolitan Area 827 82.7
Other cities in the state 171 17.1
Other states 2 0.2
Education
Illiterate 13 2.2
1 to 3 years completed 104 17.7
4 to 7 years completed 186 31.7
8 to 11 years completed 191 32.6
≥ 12 years completed 92 15.7
Menarche
< 12 years 157 17.6
≥ 12 years 735 82.4
Menopausal status
Premenopausal 681 74.4
Postmenopausal 234 25.6
Use of hormone therapy
Yes 19 2.1
No 886 97.9
Use of oral contraceptives
Yes 58 6.4
No 847 93.6
Breastfeeding
Yes 547 74.4
No 188 25.6
Age at first pregnancy
Nulliparous 95 13.4
< 30 years 556 78.5
≥ 30 years 57 8.0
Table 2. Mammographic findings in women aged 40-49 
years who underwent mammography screening. Recife, PE, 
Northeastern Brazil, 2010-2011. (N = 1,000)
Mammographic findings n %
Breast density
Dense breasts 277 27.7
Moderately dense breasts 447 44.7
Breasts partially replaced by fat 120 12.0
Breasts completely replaced by fat 156 15.6
Nodules
Circumscribed nodules 65 91.5
Noncircumscribed nodules 6 8.5
Calcifications
Benign 291 98.6
Suspicious 3 1.0
Malignant 1 0.3
Asymmetry
Yes 63 6.3
No 937 93.7
Structural distortions
Yes 3 0.3
No 997 99.7
BI-RADS
0 232 23.2
1 454 45.4
2 294 29.4
3 16 1.6
4A 2 0.2
4B 0 –
4C 1 0.1
5 1 0.1
BI-RADS: Breast Imaging-Reporting and Data System
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One of the patients with BI-RADS 4A showed dense 
right axillary lymph nodes and remains under inves-
tigation. The other patient with BI-RADS 4A could 
not be located and the mammogram showed grouped 
pinpoint calcifications. One patient with BI-RADS 4C 
and pleomorphic microcalcifications did not follow up 
for medical care.
For the purposes of bivariate analysis, women were 
divided into two groups according to BI-RADS cate-
gories (3, 4, and 5 versus 1 and 2). Because it is incon-
clusive, BI-RADS 0 cases were excluded. Higher 
frequency of women with ≥ 8 years of education 
had BI-RADS categories 3, 4, or 5 than women with 
BI-RADS 1 and 2 (4.2% versus 0.8%; PR 5.08; 95%CI 
1.11;23.3; p = 0.02). Nulliparous women had a higher 
frequency of BI-RADS categories 3, 4, and 5 (6.7% 
versus 2.6%) than others; however, this difference was 
not statistically significant (p = 0.07). For the variables 
age 45-49 years, Caucasian ethnicity, menarche at age 
< 12 years, use of hormone-replacement therapy, use 
of oral contraceptives, breastfeeding in at least one 
previous pregnancy, and age at first pregnancy ≥ 30 
years, no significant differences were detected between 
the two BI-RADS groups (Table 4).
DISCUSSION
Only one case of breast cancer was found among the 
1,000 women aged 40-49 years who underwent routine 
mammography screening. In addition, several addi-
tional procedures were performed, but the tests were 
inconclusive for many of these women.
Age continues to be one of the most important risk factors 
for breast cancer.17 Our results showed a prevalence of 
one case of breast cancer among 1,000 women aged 
40-49 years. However, the study was limited by its retro-
spective nature, and the infeasibility of obtaining histo-
pathological results for two patients with BI-RADS 4A 
and for another with BI-RADS 4C. Nevertheless, even 
considering these three cases as positive, the number of 
cases of breast cancer in the age group of 40-49 years 
would have been four per 1,000. This prevalence is less 
than that estimated by the National Cancer Institute in 
the United States (1 in 69)17 but higher than that of the 
general population. Results like these lead to controver-
sies about the need for screening in this age group by 
national and international associations.17
The American Cancer Society and the American 
College of Obstetricians and Gynecologists recommend 
universal screening for women aged 40-49 years.17 
However, according to the consensus reached between 
the US Preventive Services Task Force and the 
Canadian Task Force, routine mammography screening 
in women aged 40-49 years who are not at high risk 
is not recommended.13,17 In Brazil, the Ministry of 
Health and the National Cancer Institute (INCA) do 
not recommend routine mammography screening in 
this age group,d,e but other institutions have different 
screening protocols.
Considering the high frequency of breast cancer in 
Brazil and in the Northeast region as well as difficulties 
related to access to mammography screening, the current 
IMIP recommendation is routine examination after age 
40 years even for patients with typical risk. In addition, 
mammography should be performed annually, but this 
suggestion differs from the INCA recommendations.d
As a result of the early screening, 23.0% of the mammo-
grams yielded inconclusive results (BI-RADS 0). This 
high rate of BI-RADS 0 was probably because most 
patients had dense breast tissue, which impaired the 
quality of the examination.6,12 Only 20 women had 
BI-RADS 3-5, i.e., of the 1,000 women who under-
went screening, only 20 (2.0%) results required further 
investigation; on the other hand, 23.0% of the results 
were inconclusive (BI-RADS 0), and in the end, only 
one case was confirmed to have breast cancer. Because 
these mammograms were conducted on asymptomatic 
women, no women were classified as BI-RADS 6.
Other interventions were also performed, including 469 
ultrasound scans, 53 referrals to mastologists, 11 cyto-
logical examinations, and eight biopsies, totaling 541 
interventions. Consequently, of the 1,000 women 
who underwent mammography, > 50.0% underwent 
complementary diagnostic methods, and these exami-
nations contributed to a conclusive diagnosis in only 
a few cases. However, this study was not designed to 
address this issue. For this reason, future studies are 
Table 3. Frequency of complementary methods, procedures, 
and histopathological findings in women aged 40-49 years 
who underwent mammography screening. Recife, PE, 
Northeastern Brazil, 2010-2011. (N = 1,000)
Methods and procedures n %
Ultrasound 469 46.9
Referral to mastologists 53 5.3
Cytological examination 11 1.1
Unsatisfactory 2 0.2
Nonproliferative lesions 5 0.5
Proliferative lesions without atypia 4 0.4
Proliferative lesions with atypia 0 –
Carcinoma 0 –
Biopsy 8 0.8
Histopathological findings
Nonproliferative lesions 2 0.2
Proliferative lesions without atypia 5 0.5
Proliferative lesions with atypia 0 –
In situ carcinoma 0 –
Invasive carcinoma 1 0.1
937Rev Saúde Pública 2014;48(6):931-939
Table 4. Association of biological, sociodemographic, gynecological, and reproductive characteristics with BI-RADS categories 3, 4, 
and 5 in women aged 40-49 years who underwent mammography screening. Recife, PE, Northeastern Brazil, 2010-2011. (N = 1,000)
Variable
BI-RADS
3-4-5 1-2
p RP 95%CI  
n % n %
Age (years)
45 to 49 11 2.7 400 97.3 0.90a 1.06 0.44;2.52
40 to 44 9 2.5 347 97.5
Ethnicity
Caucasian 4 3.8 101 96.2 0.47b 1.20 0.39;3.69
Others 11 3.2 336 96.8
Education
≥ 8 years 9 4.2 207 95.8 0.02a 5.08 1.11;23.3
< 8 years 2 0.8 242 99.2
Menarche
< 12 years 3 2.6 112 97.4 0.52b 1.14 0.33;3.92
≥ 12 years 13 2.3 553 97.7
Use of hormone therapy
Yes 0 0 18 100 0.64b – –
No 17 2.5 660 97.5
Use of oral contraceptives
Yes 0 0 44 100 0.32b – –
No 17 2.6 634 97.4
Breastfeeding
Yes 11 2.7 395 97.3 0.17b 0.57 0.22;1.44
No 7 4.8 140 95.2
Age at first pregnancy
≥ 30 years 1 2.3 42 97.7 0.69b 0.90 0.12;6.83
< 30 years 11 2.6 416 97.4
Parity
Nulliparity 5 6.7 70 93.3 0.07b 2.61 0.95;7.20
≥ 1 12 2.6 458 97.4
BI-RADS: Breast Imaging-Reporting and Data System
a Chi-squared test.
b Fisher’s exact t test.
needed to compare the number of interventions in the 
40-49 age group with those of women > 50 years, and 
cost-benefit studies are needed to evaluate the cost of 
detection of one case of breast cancer and the cost of 
all examinations and interventions resulting from this 
screening. The risk group (BI-RADS categories 3, 4, 
and 5) included BI-RADS 3 because, despite having 
a low rate of malignancy (approximately 2.0%), it 
is considered a risk of developing breast cancer and 
requires complementary examinations, which may 
sometimes be unnecessary.
We do not have the natural history of the single case of 
breast cancer. It has been suggested that some cases of 
cancer diagnosed by mammography alone would never 
have been diagnosed without impacting the women’s 
survival,5 similar to cases of prostate cancer diagnosed 
by screening with PSA and/or digital rectal examina-
tion.5 The view that early detection of tumors allows 
curative treatment creates the so-called “time bias”. 
This scenario favors early detection but has not been 
supported by solid scientific evidence.3 In this respect, 
it is possible that excessive diagnostic examinations 
are being conducted and that tumors that do not require 
treatment are being treated.3
A systematic review5 involving 600,000 women found 
that 200 of them had experienced significant psycho-
logical stress for many months because of false-positive 
findings, not only up to the moment of acknowledging 
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the definitive test results but even after they were 
declared cancer free.5 In addition, when a meta-anal-
ysis was conducted for the subgroup of women aged 
< 50 years, stratified by study quality, a significant 
difference in mortality from breast cancer was observed 
in the studies with a randomized sample.5
However, another meta-analysis evaluated the effec-
tiveness of mammographic screening in decreasing 
mortality from breast cancer in women 39-49 years 
and yielded different results.10 Seven randomized 
trials were included and their joint analysis showed a 
significant reduction in mortality from breast cancer 
due to screening this age group.10 However, the studies 
included were of variable quality, and after exclusion 
of three randomized clinical trials conducted before 
1980, the overall relative risk of mortality did not 
decrease significantly (RR = 0.87; 95%CI 0.56;1.13). 
The authors discuss the importance of false-positive 
results and the adverse effects of screening on the 
possible reduction of mortality.10 Therefore, women 
should be informed about the risks and benefits of 
screening before deciding whether or not to participate 
in a regular screening program before age 50.3
Furthermore, the number of mammograms performed 
in an annual screening program starting at age 40 years 
is almost twice those performed in a program starting at 
age 50 years and is done biannually. Consequently, radia-
tion exposure is doubled.6 Although it has been argued 
that the amount of radiation from mammography is very 
low, repeated doses of radiation in more comprehen-
sive screening programs pose potential risks that should 
not be disregarded. A cohort study of 100,000 women 
showed that annual screening between 40 and 55 years 
of age and biennial screening ≤ 74 years at a dose of 
3.7 mGy for both breasts resulted in 86 radiation-induced 
cancers and 11 deaths from this type of cancer.19
It was also observed that 72.4% of mammogram results 
showed dense or moderately dense breasts. Dense 
breasts are expected for this age group,e although some 
authors suggest that this density is a risk factor for breast 
cancer.16 Consequently, the false-positive rate and the 
rate of recall for imaging studies are higher and the 
predictive value of biopsies is lower.e
In addition to age, other studies showed risk factors 
that favor mammographic screening in the age group 
of 40-49 years, including breast density, family history, 
and previous biopsies.18 In the present study, nulliparous 
women with ≥ 8 years of education had a higher risk 
of BI-RADS categories 3, 4, and 5. Therefore, future 
studies should evaluate the benefits of individualized 
screening in this age group, according to the pres-
ence of risk factors for breast cancer, in addition to the 
existing criteria for moderate risk, including nulliparity 
and family history of breast cancer after age 50 years.
The study design has some limitations. Because the 
study was conducted in a hospital that solely serves 
the Unified Health System (SUS), the profile of women 
treated at IMIP may be different from that of women 
assisted in private institutions. Therefore, it is not advis-
able to extrapolate the results to the entire population 
of women aged 40-49 years. On the basis of the results 
of the present study, it is not possible to draw conclu-
sions about mortality reduction. However, these find-
ings are relevant to SUS and should be considered when 
assessing the cost-effectiveness of the breast cancer 
screening program. The data from the Breast Cancer 
Information Systemc should be used for a large-scale 
evaluation of the results of breast cancer screening in 
Brazil, including the tests performed in the age group 
of 40-49 years. It is probable that excessive tests are 
being recommended and are not yielding consistent 
benefits for women.
However, mammography screening in women aged 
40-49 years in IMIP indicated a low frequency of breast 
cancer and led to the performance of complementary 
interventions. However, this screening increased costs 
and did not prove its efficacy in decreasing mortality. 
Therefore, the criteria recommended by INCA and the 
US and Canadian task forces should be adopted, and 
screening in women with typical risk should begin only 
at age 50 years. Before this age, biennial mammog-
raphy screening should be individualized and take into 
account the patients’ profile and expectations, including 
their own perception of the risks and benefits, while 
respecting their autonomy to decide whether to undergo 
this examination.
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